Company intelligence / Profile preview

Filterlex Medical

Caesarea, Haifa District, Israelfilterlex.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company’s lead product, the CAPTIS full-body embolic protection device, has successfully completed a first-in-human study in 20 patients undergoing TAVR. The study demonstrated 100% procedural success with no device-related complications or cerebrovascular events. CAPTIS effectively captured embolic debris and showed promise for improving safety in TAVR procedures. Ongoing development aims to further substantiate its use in TAVR and potentially other complex cardiac interventions.

Therapeutic areas: Cardiovascular
Modalities: DeviceEmbolic protection device
Industry: Surgical Medical Devices

Partnerships

Alon MedTech Ventures incubator participation/partnership

Beyond the preview

Go deeper on Filterlex Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Filterlex Medical.

Explore the full profile